SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03502330

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy

This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab. The phase 1 dose escalation portion of the study will enroll patients with advanced solid tumors melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) in 6 cohorts to determine the recommended phase II dose (RP2D) of APX005M. The phase 1b dose expansion portion will study the triple drug combination separately in the three disease cohorts: melanoma, NSCLC, and RCC. Submitted on 3/29/2018; investigational new drug (IND) number is pending and will be added to the record once received.

NCT03502330 Advanced Melanoma Non-small Cell Lung Cancer Renal Cell Carcinoma
MeSH:Carcinoma Lung Neoplasms Carcinoma, Non-Small-Cell Lung Melanoma Carcinoma, Renal Cell
HPO:Carcinoma Clear cell renal cell carcinoma Cutaneous melanoma Melanoma Neoplasm of the lung Non-small cell lung carcinoma Papillary renal cell carcinoma Renal cell carcinoma

3 Interventions

Name: APX005M

Description: APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
Type: Drug
Group Labels: 9

Cohort 1 Advanced Solid Tumors Cohort 2 Advanced Solid Tumors Cohort 3 Advanced Solid Tumors Cohort 4 Advanced Solid Tumors Cohort 5 Advanced Solid Tumors Cohort 6 Advanced Solid Tumors Cohort 7 Advanced Melanoma Cohort 8 NSCLC Cohort 9 RCC

Name: Cabiralizumab

Description: Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
Type: Drug
Group Labels: 9

Cohort 1 Advanced Solid Tumors Cohort 2 Advanced Solid Tumors Cohort 3 Advanced Solid Tumors Cohort 4 Advanced Solid Tumors Cohort 5 Advanced Solid Tumors Cohort 6 Advanced Solid Tumors Cohort 7 Advanced Melanoma Cohort 8 NSCLC Cohort 9 RCC

Name: Nivolumab

Description: Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
Type: Drug
Group Labels: 5

Cohort 2 Advanced Solid Tumors Cohort 4 Advanced Solid Tumors Cohort 6 Advanced Solid Tumors Cohort 7 Advanced Melanoma Cohort 9 RCC


Primary Outcomes

Description: AEs and SAEs will be examined with (National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03

Measure: Safety and Tolerability measured by assessing serious adverse events (SAEs)and adverse events (AEs)

Time: From study enrollment up to 12 months.

Description: This 5-point scale ranges from full functioning (1) to dead (5)

Measure: Safety and Tolerability measured by Eastern Cooperative Oncology Group(ECOG) performance status

Time: From study enrollment up to 12 months.

Secondary Outcomes

Description: ORR will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria v. 1.1.

Measure: Efficacy measured by objective response rate (ORR)

Time: Six months.

Other Outcomes

Description: This outcome will be assessed by blood collection.

Measure: Pharmacokinetics (PK) of APX005M assessed by area under the curve (AUC).

Time: 12 weeks

Description: This outcome will be assessed by blood collection.

Measure: Pharmacokinetics (PK) of APX005M assessed by minimum blood plasma concentration (Cmin).

Time: 12 weeks

Description: This outcome will be assessed by blood collection.

Measure: Pharmacokinetics (PK) of APX005M assessed by clearance (CL).

Time: 12 weeks

Description: This outcome will be assessed by blood collection.

Measure: Pharmacokinetics (PK) of APX005M assessed by volume of distribution (Vss)

Time: 12 weeks

Description: This outcome will be assessed by blood collection.

Measure: Pharmacokinetics (PK) of APX005M assessed by peak plasma concentration (Cmax).

Time: 12 weeks

Description: This outcome will be assessed with tissue biopsies.

Measure: Tissue-based pharmacodynamics (PD) of APX005M, in combination with nivolumab and cabiralizumab assessed by CD8+ T cells .

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed with tissue biopsies.

Measure: Tissue-based pharmacodynamics (PD) of APX005M, in combination with nivolumab and cabiralizumab assessed by CD163+ macrophages .

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed via blood collection.

Measure: Blood-based pharmacodynamics (PD) of APX005M, in combination with nivolumab and cabiralizumab assessed by circulating CD163+ macrophages .

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed via blood collection.

Measure: Blood-based pharmacodynamics (PD) of APX005M, in combination with nivolumab and cabiralizumab assessed by circulating CD8+ T cells.

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed via blood collection.

Measure: Cytokine-based pharmacodynamic (PD) biomarkers of APX005M, in combination with nivolumab and cabiralizumab assessed by CD40L levels.

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed via blood collection.

Measure: Cytokine-based pharmacodynamic (PD) biomarkers of APX005M, in combination with nivolumab and cabiralizumab assessed by IL-10 levels.

Time: Change from baseline to 8 weeks.

Description: This outcome will be assessed via blood collection.

Measure: Cytokine-based pharmacodynamic (PD) biomarkers of APX005M, in combination with nivolumab and cabiralizumab assessed by interferon-gamma levels .

Time: Change from baseline to 8 weeks.

Description: PFS will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria v. 1.1.

Measure: Efficacy measured by progression-free survival (PFS)

Time: From study enrollment up to 6 years.

Description: OS will be ascertained by review of the National Death Index, medical records and follow-up phone calls.

Measure: Efficacy measured by overall survival (OS)

Time: From study enrollment up to 6 years.

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 T790M

Patients with TKI-treated EGFR mutant NSCLC harboring the secondary EGFR T790M tumor must have received prior osimertinib. --- T790M ---



HPO Nodes


HPO: